Differences between clinical trials and postmarketing use.
暂无分享,去创建一个
Nicholas Moore | Bernard Bégaud | Ghada Miremont-Salamé | Annie Fourrier | Karin Martin | N. Moore | G. Miremont-Salamé | B. Bégaud | Philippe Latry | K. Martin | A. Fourrier | P. Latry
[1] R. Makuch,et al. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo. , 2000, The Journal of rheumatology.
[2] H. Wendt,et al. Celecoxib versus diclofenac in the management of osteoarthritis of the knee. , 2001, Scandinavian journal of rheumatology.
[3] J. Avorn,et al. Evaluating drugs after their approval for clinical use. , 1993, The New England journal of medicine.
[4] G. Bugeja,et al. Exclusion of elderly people from clinical research: a descriptive study of published reports , 1997, BMJ.
[5] R. Hubbard,et al. Comparison of once-daily and twice-daily administration of celecoxib for the treatment of osteoarthritis of the knee. , 2001, Clinical therapeutics.
[6] A. Pablos-Mendez,et al. Run-in periods in randomized trials: implications for the application of results in clinical practice. , 1998, JAMA.
[7] M. Goldenberg,et al. Celecoxib, a selective cyclooxygenase-2 inhibitor for the treatment of rheumatoid arthritis and osteoarthritis. , 1999, Clinical therapeutics.
[8] P. Solomon,et al. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group. , 1994, JAMA.
[9] N. Wieringa,et al. Co‐morbidity of ‘Clinical Trial’ versus ‘Real‐World’ patients using cardiovascular drugs , 2000, Pharmacoepidemiology and drug safety.
[10] J. Slattery,et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. , 1994, Atherosclerosis. Supplements.
[11] O. Faergeman,et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S) , 1997, Circulation.
[12] N. Black. Why we need observational studies to evaluate the effectiveness of health care , 1996, BMJ.
[13] R. Hubbard,et al. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis , 2001, American Journal of Gastroenterology.
[14] N. Wieringa,et al. Cardiovascular drugs: discrepancies in demographics between pre- and post-registration use , 1999, European Journal of Clinical Pharmacology.
[15] E. Vesell,et al. Underrepresentation of women in clinical drug trials , 1993, Clinical pharmacology and therapeutics.
[16] P. Isakson,et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: a randomized controlled trial. , 1999, Mayo Clinic proceedings.
[17] M. Gandelman. Celecoxib: a selective cyclooxygenase-2 inhibitor , 2003, Arthritis Research & Therapy.
[18] D. Graham,et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. , 1999, JAMA.
[19] M Farlow,et al. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. , 1992, JAMA.
[20] Gastone G. Celesia,et al. A 30-Week Randomized Controlled Trial of High-Dose Tacrine in Patients With Alzheimer's Disease , 1994 .
[21] P. Isakson,et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison , 1999, The Lancet.
[22] L. Tive. Celecoxib clinical profile. , 2000, Rheumatology.